Why the study?
Despite guideline recommendations, anticoagulation reversal is inconsistently used in oral anticoagulant-related intracerebral hemorrhage, particularly in severe presentations.
Does anticoagulation reversal reduce mortality in patients with oral anticoagulant-related intracerebral hemorrhage?
Population
891 consecutive OAC-related ICH patients admitted to 18 Spanish stroke centers
Comparison
Anticoagulation reversal vs no reversal
Design
Prospective multicenter registry study
Follow-up
90 days
Key result
Anticoagulation reversal in OAC-related intracerebral hemorrhage was independently associated with lower 24-hour (aOR 0.32; 95% CI 0.18-0.56) and 90-day mortality (aOR 0.59; 95% CI 0.35-0.99).
Authors
Loading...
Reversal in DOAC-ICH was associated with better outcomes; reinforces ESO guidelines and extends adjusted real-world evidence.**[[1]](https://pmc.ncbi.nlm.nih.gov/articles/PMC6921939/)[[2]](https://journals.sagepub.com/doi/abs/10.
Observational (n=891)
Yes
Does anticoagulation reversal reduce mortality in patients with oral anticoagulant-related intracerebral hemorrhage?
Effect estimate: aOR 0.32 (95% CI 0.18-0.56)
Anticoagulation reversal in OAC-related ICH is associated with significantly reduced 24-hour and 90-day mortality, including in severe cases.
Rodriguez-Luna et al. (2026) conducted an observational in Oral anticoagulant-related intracerebral hemorrhage (n=891). Anticoagulation reversal vs. No reversal was evaluated on 24-hour mortality (aOR 0.32, 95% CI 0.18-0.56). Anticoagulation reversal in OAC-related intracerebral hemorrhage was independently associated with lower 24-hour (aOR 0.32; 95% CI 0.18-0.56) and 90-day mortality (aOR 0.59; 95% CI 0.35-0.99).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: